Atrial Fibrillation Detected before or after Stroke: Role of Anticoagulation.


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
07 2023
Historique:
revised: 21 03 2023
received: 12 12 2022
accepted: 23 03 2023
medline: 30 6 2023
pubmed: 29 3 2023
entrez: 28 3 2023
Statut: ppublish

Résumé

Atrial fibrillation (AF) known before ischemic stroke (KAF) has been postulated to be an independent category with a recurrence risk higher than that of AF detected after stroke (AFDAS). However, it is unknown whether this risk difference is confounded by pre-existing anticoagulation, which is most common in KAF and also indicates a high ischemic stroke recurrence risk. Individual patient data analysis from 5 prospective cohorts of anticoagulated patients following AF-associated ischemic stroke. We compared the primary (ischemic stroke recurrence) and secondary outcome (all-cause death) among patients with AFDAS versus KAF and among anticoagulation-naïve versus previously anticoagulated patients using multivariable Cox, Fine-Gray models, and goodness-of-fit statistics to investigate the relative independent prognostic importance of AF-category and pre-existing anticoagulation. Of 4,357 patients, 1,889 (43%) had AFDAS and 2,468 (57%) had KAF, while 3,105 (71%) were anticoagulation-naïve before stroke and 1,252 (29%) were previously anticoagulated. During 6,071 patient-years of follow-up, we observed 244 recurrent strokes and 661 deaths. Only pre-existing anticoagulation (but not KAF) was independently associated with a higher hazard for stroke recurrence in both Cox and Fine-Gray models. Models incorporating pre-existing anticoagulation showed better fit than those with AF category; adding AF-category did not result in better model fit. Neither pre-existing anticoagulation nor KAF were independently associated with death. Our findings challenge the notion that KAF and AFDAS are clinically relevant and distinct prognostic entities. Instead of attributing an independently high stroke recurrence risk to KAF, future research should focus on the causes of stroke despite anticoagulation to develop improved preventive treatments. ANN NEUROL 2023;94:43-54.

Sections du résumé

BACKGROUND
Atrial fibrillation (AF) known before ischemic stroke (KAF) has been postulated to be an independent category with a recurrence risk higher than that of AF detected after stroke (AFDAS). However, it is unknown whether this risk difference is confounded by pre-existing anticoagulation, which is most common in KAF and also indicates a high ischemic stroke recurrence risk.
METHODS
Individual patient data analysis from 5 prospective cohorts of anticoagulated patients following AF-associated ischemic stroke. We compared the primary (ischemic stroke recurrence) and secondary outcome (all-cause death) among patients with AFDAS versus KAF and among anticoagulation-naïve versus previously anticoagulated patients using multivariable Cox, Fine-Gray models, and goodness-of-fit statistics to investigate the relative independent prognostic importance of AF-category and pre-existing anticoagulation.
RESULTS
Of 4,357 patients, 1,889 (43%) had AFDAS and 2,468 (57%) had KAF, while 3,105 (71%) were anticoagulation-naïve before stroke and 1,252 (29%) were previously anticoagulated. During 6,071 patient-years of follow-up, we observed 244 recurrent strokes and 661 deaths. Only pre-existing anticoagulation (but not KAF) was independently associated with a higher hazard for stroke recurrence in both Cox and Fine-Gray models. Models incorporating pre-existing anticoagulation showed better fit than those with AF category; adding AF-category did not result in better model fit. Neither pre-existing anticoagulation nor KAF were independently associated with death.
CONCLUSION
Our findings challenge the notion that KAF and AFDAS are clinically relevant and distinct prognostic entities. Instead of attributing an independently high stroke recurrence risk to KAF, future research should focus on the causes of stroke despite anticoagulation to develop improved preventive treatments. ANN NEUROL 2023;94:43-54.

Identifiants

pubmed: 36975022
doi: 10.1002/ana.26654
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-54

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Références

Ann Neurol. 2019 Jun;85(6):823-834
pubmed: 30980560
Neurology. 2016 Nov 1;87(18):1856-1862
pubmed: 27694266
J Am Coll Cardiol. 2020 Dec 8;76(23):2768-2785
pubmed: 33272372
Stroke. 2021 Nov;52(11):3472-3481
pubmed: 34311567
Eur Neurol. 2016;76(3-4):187-193
pubmed: 27705975
J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):320-325
pubmed: 30455404
J Thromb Thrombolysis. 2016 Oct;42(3):393-8
pubmed: 27329483
Int J Stroke. 2015 Aug;10(6):836-42
pubmed: 25581108
Cerebrovasc Dis. 2022;51(2):152-157
pubmed: 34844239
Stroke. 2022 Mar;53(3):e94-e103
pubmed: 34986652
Lancet Neurol. 2018 Jun;17(6):539-547
pubmed: 29778365
J Neurol Neurosurg Psychiatry. 2021 Oct;92(10):1062-1067
pubmed: 33903185
J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):588-598
pubmed: 35396339
J Stroke Cerebrovasc Dis. 2016 Sep;25(9):2317-21
pubmed: 27449113
Eur Stroke J. 2022 Sep;7(3):221-229
pubmed: 36082252
Ann Neurol. 2020 Feb 12;:
pubmed: 32052481
Ann Neurol. 2022 Jan;91(1):78-88
pubmed: 34747514
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
Curr Opin Neurol. 2017 Feb;30(1):28-37
pubmed: 27984303
Eur Stroke J. 2020 Dec;5(4):384-393
pubmed: 33598557
Neurology. 2018 Mar 13;90(11):e924-e931
pubmed: 29444969
Eur J Neurol. 2022 Jul;29(7):1963-1971
pubmed: 35344638
Stroke. 2019 May;50(5):1124-1129
pubmed: 31009353
J Neurol Neurosurg Psychiatry. 2022 Feb;93(2):119-125
pubmed: 34635567
Circ J. 2018 Jun 25;82(7):1935-1942
pubmed: 29863095
Lancet Neurol. 2018 Dec;17(12):1109-1120
pubmed: 30509695
J Stroke Cerebrovasc Dis. 2012 Nov;21(8):726-31
pubmed: 21546265
Curr Med Res Opin. 2022 Jan;38(1):7-18
pubmed: 34632887
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
Stroke. 2020 Apr;51(4):1150-1157
pubmed: 32098607
Int J Cardiol. 2018 Jun 15;261:68-72
pubmed: 29657060
Eur J Neurol. 2020 Aug;27(8):1612-1617
pubmed: 32333493

Auteurs

Flurina Lyrer (F)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.

Annaelle Zietz (A)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
Neurology and Neurorehabilitation, University Hospital for Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.

David J Seiffge (DJ)

Department of Neurology, Inselspital University Hospital Bern, University of Bern, Bern, Switzerland.

Masatoshi Koga (M)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Bastian Volbers (B)

Department of Neurology, University Hospital Erlangen, Erlangen, Germany.

Duncan Wilson (D)

Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
New Zealand Brain Research Institute, Christchurch, New Zealand.

Bruno Bonetti (B)

Stroke Unit - Department of Neuroscience, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Sabine Schaedelin (S)

Clinical Trial Unit, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.

Henrik Gensicke (H)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
Neurology and Neurorehabilitation, University Hospital for Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.

Sohei Yoshimura (S)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Kosmas Macha (K)

Department of Neurology, University Hospital Erlangen, Erlangen, Germany.

Gareth Ambler (G)

Department of Statistical Science, University College London, London, UK.

Sebastian Thilemann (S)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.

Tolga Dittrich (T)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.

Manabu Inoue (M)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Kaori Miwa (K)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Ruihao Wang (R)

Department of Neurology, University Hospital Erlangen, Erlangen, Germany.

Gabriela Siedler (G)

Department of Neurology, University Hospital Erlangen, Erlangen, Germany.

Luise Biburger (L)

Department of Neurology, University Hospital Erlangen, Erlangen, Germany.

Martin M Brown (MM)

Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.

Rolf H Jäger (RH)

Lysholm Department of Neuroradiology and the Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK.

Keith Muir (K)

Institute of Neuroscience & Psychology, University of Glasgow and Queen Elizabeth University Hospital, Glasgow, UK.

Christopher Traenka (C)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
Neurology and Neurorehabilitation, University Hospital for Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.

Kanta Tanaka (K)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Masayuki Shiozawa (M)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Leo H Bonati (LH)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
Reha Rheinfelden, Rheinfelden, Switzerland.

Nils Peters (N)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
Neurology and Neurorehabilitation, University Hospital for Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.
Stroke Center, Klinik Hirslanden, Zurich, Switzerland.

Gregory Y H Lip (GYH)

Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Philippe A Lyrer (PA)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.

Manuel Cappellari (M)

Stroke Unit - Department of Neuroscience, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Kazunori Toyoda (K)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Bernd Kallmünzer (B)

Department of Neurology, University Hospital Erlangen, Erlangen, Germany.

Stefan Schwab (S)

Department of Neurology, University Hospital Erlangen, Erlangen, Germany.

David J Werring (DJ)

Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.

Stefan T Engelter (ST)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
Neurology and Neurorehabilitation, University Hospital for Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.

Gian Marco De Marchis (GM)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.

Alexandros A Polymeris (AA)

Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH